- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cervical cancer
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 2MB)
Pembrolizumab – November 2022
Pembrolizumab (cervical cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
3 March 2023